Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Non-Coding Rnas Affecting Nlrp3 Inflammasome Pathway in Diabetic Cardiomyopathy: A Comprehensive Review of Potential Therapeutic Options Publisher Pubmed



Radmehr E1, 3 ; Yazdanpanah N2, 3, 4 ; Rezaei N2, 3, 5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Colorectal Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences (TUMS), Tehran, Iran
  2. 2. Research Center for Immunodeficiencies, Children’s Medical Center Hospital, Tehran University of Medical Sciences, Dr. Qarib St, Keshavarz Blvd, Tehran, 14194, Iran
  3. 3. Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran
  4. 4. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Source: Journal of Translational Medicine Published:2025


Abstract

Cardiomyopathies are a heterogeneous group of disorders that can lead to fulminant heart failure and sudden cardiac death. In recent years, the prevalence of all types of cardiomyopathies has shown an upward trend globally. Up to 40% of patients with cardiomyopathy-related heart failure have diabetes mellitus (DM). With the fast global spread of DM, the prevalence of DCM is increasing accordingly and it remains the leading cause of morbidity and mortality in chronic diabetic patients. NLRP3 inflammasome significantly contributes to the development and pathological progression of DCM. Targeting the inflammasome or any of the mediators along its activation pathway provides new potential therapeutic targets for developing specialized drugs to treat DCM. In this comprehensive review, we sought to introduce and summarize the non-coding RNAs with potential therapeutic effects targeting NLRP3 inflammasome signaling in DCM. We hope this general overview can aid future research in developing new therapies for DCM. © The Author(s) 2025.
Other Related Docs
12. The Role of Inflammasome Complex in Ischemia-Reperfusion Injury, Journal of Cellular Biochemistry (2023)
16. Inflammasome: Its Role in Traumatic Brain and Spinal Cord Injury, Journal of Cellular Physiology (2018)
18. Infection and Immunity, Clinical Immunology (2022)
20. Caspase-1 Inhibition Prevents Glial Inflammasome Activation and Pyroptosis in Models of Multiple Sclerosis, Proceedings of the National Academy of Sciences of the United States of America (2018)
22. Intravenous Immunoglobulin Therapy in Myocarditis, Iranian Journal of Allergy# Asthma and Immunology (2020)
30. Cardiogenetics: Genetics for Cardiologists, Journal of Knowledge and Health in Basic Medical Sciences (2022)